Literature DB >> 27758955

The impact of adjusted work conditions and disease-modifying drugs on work ability in multiple sclerosis.

Anne Wickström1, Maria Fagerström2, Lucas Wickström3, Gabriel Granåsen4, Charlotte Dahle5, Magnus Vrethem6, Peter Sundström1.   

Abstract

BACKGROUND: Multiple sclerosis (MS) is a neurological disorder that causes significantly reduced ability to work, and the Expanded Disability Status Scale (EDSS) is one of the main predictors for reduced work ability.
OBJECTIVES: To investigate how work requirements, flexible work conditions and disease-modifying drugs (DMDs) influence the work ability in relation to different EDSS grades in two MS populations.
METHODS: Work ability was studied in two MS populations: one in the southern and one in the northern part of Sweden, both demographically similar. In the latter population, more active work-promoting interventions have been practised and second-generation DMDs have been widely used from the onset of disease for several years.
RESULTS: The proportion of MS patients who participated in the workforce or studied was significantly higher in the northern compared with the southern population ( p < 0.001). The employees in the northern population had significantly lower requirements, greater adapted work conditions and were able to work more hours per week. Higher EDSS was associated with lower reduction in number of worked hours per week in the northern population ( p = 0.042).
CONCLUSION: Our data indicated that treatment strategy and adjusted work conditions have impact on work ability in MS.

Entities:  

Keywords:  Multiple sclerosis; Work Ability Questionnaire – Multiple Sclerosis; adjusted work conditions; disease-modifying drugs; work requirements; working ability

Mesh:

Substances:

Year:  2016        PMID: 27758955     DOI: 10.1177/1352458516671818

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  3 in total

1.  Occupational outcomes of people with multiple sclerosis: a scoping review.

Authors:  Bruno Kusznir Vitturi; Alborz Rahmani; Guglielmo Dini; Alfredo Montecucco; Nicoletta Debarbieri; Elvira Sbragia; Paolo Bandiera; Michela Ponzio; Mario Alberto Battaglia; Tommaso Manacorda; Benedetta Persechino; Giuliana Buresti; Matilde Inglese; Paolo Durando
Journal:  BMJ Open       Date:  2022-07-01       Impact factor: 3.006

2.  Validation of the Swedish Multiple Sclerosis Register: Further Improving a Resource for Pharmacoepidemiologic Evaluations.

Authors:  Peter Alping; Fredrik Piehl; Annette Langer-Gould; Thomas Frisell
Journal:  Epidemiology       Date:  2019-03       Impact factor: 4.822

3.  Work and everyday life in a digitalized time: Experiences of people with subjective cognitive difficulties related to neurological disorders.

Authors:  Monika Lindberg; Maria Ranner; Eva Månsson-Lexell; Lars Jacobsson; Maria Larsson-Lund
Journal:  PLoS One       Date:  2021-11-15       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.